Terns Pharmaceuticals Inc TERN.OQ TERN.O is expected to show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Terns Pharmaceuticals Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 13.8% in the last three months.
Wall Street's median 12-month price target for Terns Pharmaceuticals Inc is $20.00, above its last closing price of $3.00.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.28 | -0.28 | -0.26 | Beat | 7.1 |
Dec. 31 2025 | -0.34 | -0.31 | -0.24 | Beat | 22.6 |
Sep. 30 2024 | -0.32 | -0.32 | -0.28 | Beat | 12.6 |
Jun. 30 2024 | -0.34 | -0.34 | -0.31 | Beat | 8.8 |
Mar. 31 2024 | -0.34 | -0.34 | -0.30 | Beat | 11.1 |
Dec. 31 2023 | -0.29 | -0.29 | -0.29 | Met | 0.8 |
Sep. 30 2023 | -0.31 | -0.31 | -0.42 | Missed | -37.5 |
Jun. 30 2023 | -0.34 | -0.34 | -0.25 | Beat | 26.2 |
This summary was machine generated May 9 at 15:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。